|Articles|March 1, 2019
- Pharmaceutical Executive-03-01-2019
- Volume 39
- Issue 3
Pharmaceutical Executive, March 2019 Issue (PDF)
Click the title above to open the Pharmaceutical Executive March 2019 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 6 years ago
Patient Advocacy: The Corporate Mandateover 6 years ago
Patient Support Programs: Cost, Benefit, and Resourcingover 6 years ago
Patients is a Virtueover 6 years ago
What Does Patient Centricity Look Like?over 6 years ago
John Crowley: Living the Missionover 6 years ago
Research Bonds Strengthenover 6 years ago
Parallel Trade a Victim of Brexit Collateral Damageover 6 years ago
Multiple Pharma Issues Top Congressional Agendaover 6 years ago
Pharm Exec Joins MJH Portfolioover 6 years ago
Cystic Fibrosis: The Importance of Patient AdvocacyNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Merck Planning $70 Billion Investment for US Expansion
2
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
